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Abstract
Duchenne muscular dystrophy (DMD) is an X-linked, fatal muscle wasting disease for which there is currently no cure and
limited palliative treatments. Poloxomer 188 (P188) is a tri-block copolymer that has been proposed as a potential treatment
for cardiomyopathy in DMD patients. Despite the reported beneficial effects of P188 on dystrophic cardiac muscle function,
the effects of P188 on dystrophic skeletal muscle function are relatively unknown. Mdx mice were injected intraperitoneally
with 460 mg/kg or 30 mg/kg P188 dissolved in saline, or saline alone (control). The effect of single-dose and 2-week daily
treatment was assessed using a muscle function test on the Tibialis Anterior (TA) muscle in situ in anaesthetised mice. The
test comprises a warm up, measurement of the force-frequency relationship and a series of eccentric contractions with a
10% stretch that have previously been shown to cause a drop in maximum force in mdx mice. After 2 weeks of P188
treatment at either 30 or 460 mg/kg/day the drop in maximum force produced following eccentric contractions was
significantly greater than that seen in saline treated control mice (P = 0.0001). Two week P188 treatment at either dose did
not significantly change the force-frequency relationship or maximum isometric specific force produced by the TA muscle.
In conclusion P188 treatment increases susceptibility to contraction-induced injury following eccentric contractions in
dystrophic skeletal muscle and hence its suitability as a potential therapeutic for DMD should be reconsidered.
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Introduction
Duchenne muscular dystrophy (DMD) is an X-linked, fatal
muscle wasting disease for which there is currently no cure and
limited palliative treatments. DMD is caused by the loss of
functional dystrophin protein, primarily resulting from frame-
shifting mutations in the dystrophin gene [1]. Dystrophin, and its
dystrophin-associated glycoprotein complex connect the extracel-
lular matrix to the cytoskeleton of myofibres and anchor
subsarcolemmal neuronal nitric oxide synthase (nNOS) [2]. The
lack of dystrophin in DMD muscle increases the permeability of
the sarcolemma, particularly during lengthening or ‘‘eccentric’’
contractions [3] such as those performed while walking down
stairs. The mechanism behind this is controversial. Traditionally it
was thought that the lack of sarcolemmal stabilisation during
muscle contractions resulted in membrane tearing causing an
influx of calcium [4,5]. However it has since been demonstrated
that stretching dystrophic muscle fibres opens stretch-activated
calcium channels, which remain closed in normal muscle [6,7],
and that blocking these channels pharmacologically reduces
dystrophic pathology following a period of eccentric contractions
[7].
Despite this the ‘‘membrane sealant’’ Poloxamer-188 has
received attention as a potential therapeutic in DMD [8–10].
Poloxamer-188 (P188, or Pluronic F68) is a non-ionic tri-block
copolymer of poly(ethylene oxide)80-poly(propylene oxide)27-poly(-
ethylene oxide)80 with an approximate molecular weight of
8.4 kDa [11]. P188 is amphiphilic, with a hydrophobic midsection
that inserts into areas of low membrane tension, such as areas of
membrane damage [12]. P188 has been shown to act as a
membrane sealant following a variety of types of injury. In neural
tissue P188 was shown to reduce brain damage following
ischemia/reperfusion injury in vivo [13]. In skeletal muscle
intravenous P188 reduced tissue oedema and inflammation in
flexor digitorum brevis muscles of rats following electric shock [14] and
improved myocyte survival after exposure to ionising radiation in
vitro [15].
In dystrophic muscle P188 has primarily been studied as a
potential cardioprotective agent with beneficial effects of system-
ically administered P188 reported in both dystrophic mouse (mdx)
and dog (Golden Retriever Muscular Dystrophy (GRMD)) models
[8–10]. In mdx mice both single dose and 2-week treatment with
P188 improved left ventricular function and increased survival
after challenges with cardiac stimulants [8,10]. In the more
severely affected GRMD dog an 8-week constant rate infusion of
P188 resulted in reduced myocardial fibrosis and left ventricular
remodelling (Townsend et al. 2010). To date the effect of P188 on
skeletal muscle function has only been studied in vitro. A modest
reduction in isometric contraction-induced force decline was seen
in mdx lumbrical (toe) muscles bathed in P188 in vitro [16] and 2 or
4 weeks of systemic P188 treatment had no effect on specific force
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production by excised extensor digitorum longus (EDL) muscles [10].
However very little is known about the effect of P188 on skeletal
muscle function in vivo.
P188 has previously reached phase III clinical trials as a
rheologic agent for the treatment of sickle cell crisis [17,18].
Similar compounds have also been used to facilitate delivery of
chemotherapeutics to tumours [19]. In this case poloxamer
compounds (or ‘‘pluronics’’) are used to disrupt the plasma
membrane of tumour cells by disturbing lipid packing [20],
increasing phospholipid flip flop [21], and causing ATP depletion
[22]. This approach has also been used to enhance gene delivery
to several tissues including skeletal muscle [23]. Therefore the
addition of P188 to the sarcolemma is unlikely to be a benign
event. The hypothesis for this study was therefore that P188 would
have a deleterious effect on skeletal muscle function in vivo,
particularly when the membrane is subjected to mechanical stress.
Materials and Methods
Ethical approval
All animal experiments were carried out under license from the
Home Office (UK) in accordance with The Animals (Scientific
Procedures) Act 1986 and were approved by Royal Veterinary
College ethical committee. All mice were housed in a minimal
disease facility and had ad libitum access to food and water.
Animals
Homozygous female mdx mice were used for muscle function
studies and male mdx mice were used for the tail vein bleeding time
assay. All mice in the P188 study were 9–11 months old.
Littermates (and cagemates) were distributed across the three
treatment groups with 7–9 mice in each group in a randomised
block design. In addition, data is provided from female 6-month
old mdx (n = 5) and C57BL/10 mice (n = 7) to illustrate the
difference in contraction-induced injury between mdx mice and
their background wild-type strain.
Drug treatment for muscle electrophysiology studies
P188 was dissolved in sterile saline to form a 100 mg/ml stock
solution. Treated mdx mice either received 460 mg/kg [10,14]
P188 or 30 mg/kg P188 [18]. Control mice received saline alone.
All solutions were made up to 0.2 ml with saline and given by
intraperitoneal (IP) injection. Peak plasma concentrations of P188
have been reported to occur between 20 and 120 mins after IP
injection [24].
For the single-dose study mice were weighed on the day of
surgery and injected with either P188 or saline 15 minutes prior to
the induction of anaesthesia. The eccentric contraction protocol
therefore started approximately 90 minutes after drug adminis-
tration. For the 2-week dose study mice were injected daily at the
same time in the morning for 2 weeks. Mice were weighed twice a
week throughout treatment. Muscle function measurements were
made in the afternoon to try to avoid any acute effects of treatment
that may have occurred during the peak plasma concentrations.
In situ TA muscle function testing
Muscle force measurements were made using an in vivo protocol
that has been described previously [25,26]. Mice were deeply
anaesthetised with fentanyl/fluanisone (Hypnorm) and midazolam
(Hypnovel) given by intraperitoneal (IP) injection. Solutions of
Hypnorm, water for injection and Hypnovel were made in a
volume ratio of 1:2:1 and administered at 8 ml/g. Anaesthesia was
maintained with further IP injections so that the animal remained
insensitive to toe pinch and surgical stimuli. Surgical preparation
of the TA tendon and the common peroneal branch of the sciatic
nerve and subsequent data acquisition were conducted with the
animal on an electric heat pad under a light source to maintain
normothermia. Exposed tissues were kept moist by frequent
irrigation with warm saline.
After an initial warm up protocol of 5 submaximal stimulations
1 minute apart the muscle’s optimum length (Lo) was determined
by measuring a series of twitches at increasing resting tensions.
The resting tension that produced the strongest twitch was then
used throughout the protocol and this twitch was recorded and
used for measurement of time to peak tension (TTPT, ms) and
half-relaxation time (ms). A series of stimulations at 10, 30, 40, 50,
80, 100, 120, 150 and 180 Hz were delivered 1 minute apart to
measure the force-frequency relationship. The maximum isomet-
ric tetanic force (Po) was determined from the plateau of the force-
frequency curve. Muscle length was measured using digital
calipers. Total functional muscle fibre cross-sectional area (CSA
in cm2) was calculated by dividing the muscle weight in grams by
the product of the TA fibre length (Lf; cm)6the density of
mammalian skeletal muscle (1.06 g/cm3). Because the TA is a
pennate muscle, Lf is 60% of the measured optimal length [27].
Specific force (N/cm2) was calculated by dividing the absolute
force (N) at each stimulation frequency by TA muscle cross-
sectional area. Specific force was plotted against frequency and
curves are compared using a Two-way Repeated Measures
Analysis of Variance (2-way RM ANOVA) with Tukey’s post-hoc
comparison. A representative graph of the force-frequency
relationship in female C57BL/10 and mdx mice is provided in
Figure 1A.
The muscle was then allowed to rest for 5 minutes before the
eccentric contraction protocol was initiated. This protocol uses a
physiologically relevant stretch of 10% of L0 that does not cause a
drop in isometric force in wild-type mice (Figure 1B and [25]) in
contrast to greater stretches of 15% over the same time period
[26]. A tetanic contraction was induced using a stimulus of 120 Hz
for 700 ms. During the last 200 ms of this contraction the muscle
was stretched by 10% of Lo at a velocity of 0.5 Lo s
21 and then
relaxed at 20.5 Los
21 following the end of the stimulus. The
muscle was subjected to 10 eccentric contractions, delivered
2 minutes apart to avoid the confounding effect of muscle fatigue.
The mouse was then euthanised by cervical dislocation and the
stimulated muscle was immediately carefully removed and
weighed. The isometric force recorded prior to the first stretch
was used as a baseline. The isometric force prior to each
subsequent stretch was measured and expressed as a percentage of
this baseline force. Isometric force was plotted against eccentric
contraction number and curves were compared using a 2-way RM
ANOVA with Tukey’s post-hoc comparison. Mice that did not
complete the full protocol (either due to technical difficulties or
death under anaesthesia) were excluded prior to statistical analysis.
Preparation of muscle sections
Mice were dissected immediately after euthanasia. Muscles were
mounted on cork discs, coated with Cryo-M-Bed and snap frozen
in liquid nitrogen cooled isopentane then stored at 280uC until
sectioning. Following a period of equilibration muscles were cut in
serial transverse, 10 mm thick sections using a Bright cryostat at
225uC. Sections were collected onto 12 SuperfrostTM slides every
300 mm along the whole length of the muscle. Slides were allowed
to dry then stored at 280uC until staining.
Staining of muscle sections
Slides were allowed to dry for 30 minutes before staining. For
all stains all 8–12 sections on each slide were stained thereby
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allowing analysis of up to 8–12 levels along the length of the
muscle.
H&E staining was used to assess muscle histopathology. Slides
were rehydrated in distilled water, stained for 2 minutes in
Harris’s Haematoxylin, dipped in acid alcohol, placed in running
tap water for 3 minutes, stained for 2 minutes in Eosin then
dehydrated through graded alcohols, cleared in xylene and
mounted using DPX.
Alizarin red was used to identify increased levels of intra-
cellular calcium in exercised and unexercised TA muscle. Sections
were fixed in cold acetone for 10 minutes then air-dried. Dried
sections were rinsed in distilled water then placed in a filtered
alizarin red solution for 1 minute. Slides were blotted, rinsed in
acetone for 30 seconds, then rinsed in a 1:1 solution of
acetone:xylene for 15 seconds before being cleared in xylene and
mounted. Fibres containing increased levels of bound calcium
stain dark red. The alizarin red solution was made by dissolving
2 g of Alizarin Red S (sodium alizarin sulphonate) in 100 ml
distilled water and adjusting to pH 4.2 with hydrochloric acid.
Staining for intracellular IgG was used to indicate increased
permeability of the sarcolemma. Intracellular IgG staining was
chosen because it yields similar results to measuring Evans Blue
Figure 1. Typical force frequency relationships and response to eccentric exercise in mdx and C57BL/10 mice. TA muscles from
anaesthetised female 6 month old mdx (n = 5) and C57BL/10 mice (n = 7) underwent a series of isometric contractions in situ induced by stimulation
of the common peroneal nerve using 1.3v at 10, 30, 40, 50, 80, 100, 120, 150 and 180 Hz. Mdx mice were significantly stronger than C57Bl/10 mice
when absolute force (N) is compared at each frequency (A). However C56Bl/10 mice were significantly stronger than mdx when force was normalised
to TA muscle cross sectional area (Specific force N/cm2; B). Following the isometric contraction protocol a series of eccentric contractions of the TA in
situ was induced by stimulation of the common peroneal nerve at 120 Hz and simultaneously stretching the TA by 10% of its optimum length.
Tetanic force was measured prior to each stretch and expressed as a percentage of the baseline force recorded prior to the first stretch (C). No drop in
force occurred in C57Bl/10 mice after 10 eccentric contractions, however the force produced by mdx mice was significantly weaker than C57Bl/10s
from contraction 2 onwards, dropping to 35% of baseline by contraction 10, ***P,0.001, **** P,0.0001. Error bars represent SEM.
doi:10.1371/journal.pone.0091221.g001
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Dye uptake but does not require the mice to be injected [28].
Dried slides were rehydrated in phosphate buffered saline
containing 0.05% tween 20 (PBST), blocked using an avidin
biotin blocking kit (Vector Laboratories, UK) then washed in
PBST. Sections were incubated at room temperature with a
biotinylated anti-mouse IgG antibody (Mouse on Mouse Kit,
Vector Laboratories, UK, diluted 1:50 in PBST). Sections were
then washed and developed using an ABC kit (Vector Laborato-
ries, UK) and metal enhanced DAB (Sigma) staining. Fibres
containing intracellular IgG stained dark grey against a pale grey
background.
Quantification of histologic parameters
Slides were evaluated blind to sample identity using a Leica
DMLB microscope and Q-Capture software. Muscle pathology
was assessed in the largest section from the mid-belly of each TA.
The number of alizarin red positive, IgG positive and hypercon-
tracted fibres present in each H & E section were manually
counted. Hypercontracted fibres are enlarged, rounded and stain
strongly with eosin (hypereosinophilic). In addition a qualitative
5 point scoring system was used to score exercised and unexercised
TA muscles based on the level of necrosis, inflammatory cell
infiltrate, fibrosis, interstitial oedema and grossly damaged fibres
present (Figure S1). Data were analysed using unpaired t-tests or
one-way AVOVA and Tukey’s post-hoc comparison where
appropriate.
Tail vein bleeding time assay (TVBT)
Mice were injected each morning for 2 weeks, and were
weighed twice a week during treatment. On the afternoon of the
last dose the mice were anaesthetized with isofluorane and a
TVBT assay was performed as previously described [29]. An
incision was made over the right lateral tail vein and the tail was
placed into a falcon tube of saline, pre-warmed to 37uC. Bleeding
was timed from incision to cessation. Mice were then euthanised
by cervical dislocation. Data were analysed using a one-way
ANOVA and Tukey’s post-hoc comparison.
Results
Typical force-frequency relationship and response to
eccentric exercise in mdx and C57BL/10 mice
During the force-frequency protocol the TA muscles of mdx
mice produced greater absolute force (N) during isometric
contractions than those of C57Bl/10 mice at each frequency
(P = 0.025, Figure 1A), however when force was normalised to TA
muscle cross sectional area (N/cm2) mdx TA muscles were
markedly weaker than those of C57Bl/10 mice
(P,0.0001,Figure 1B). During the eccentric contraction protocol
no drop in force output occurred in the TA muscles of C57Bl/10
mice after 10 eccentric contractions, however the force produced
by mdx mice was weaker than C57Bl/10s from contraction 2
onwards, dropping to 35% of baseline by contraction 10
(P,0.0001, Figure 1C).
P188 study
There was no significant change in body mass throughout the
experiment in any of the treatment groups. There was no
difference in mean body mass between treatment groups within
the cohorts of female and male mice. All animals completed the
treatment with no negative clinical signs.
Single dose P188 treatment induced a mild increase in
specific force
Over a range of frequencies from 10 to 180 Hz single-dose
P188 treatment induced a mild increase in TA specific force
(P= 0.03, RM ANOVA). On post-hoc analysis (Tukey’s) the
30 mg/kg P188 treatment group were stronger than the saline
group when stimulated at 120 Hz (P,0.05) with specific forces of
15.2960.59 N/cm2 and 13.5560.48 N/cm2 respectively
(Figure 2A). Maximum specific forces were 14.7860.44 N/cm2
(saline), 16.2760.59 N/cm2 (30 mg/kg P188) and
16.2160.46 N/cm2 (460 mg/kg P188), and were not significantly
different. No differences were detected in specific twitch tension,
time to peak tension or half relaxation time between the 3 groups
(data not shown). After 10 eccentric contractions the mean TA
tetanic forces were 3962.31% and 27.964.33% of the first
contraction in saline and 30 mg/kg P188 treated mice respective-
ly, however this was not statistically significant (Figure 2C).
Two-weeks of daily P188 did not change TA muscle
specific force
In contrast to the single dose study in which mice were injected
15 minutes prior to surgery, two-weeks of daily P188 treatment
did not significantly change the specific force produced by the TA
over the same range of frequencies (Figure 2B). Maximum specific
forces were 16.7460.83 N/cm2 (saline), 16.0260.65 N/cm2
(30 mg/kg P188) and 16.160.56 N/cm2 (460 mg/kg P188). No
significant differences were detected in specific twitch tension, time
to peak tension or half relaxation time between the 3 groups (data
not shown).
Mice treated for two-weeks with either 460 mg/kg or
30 mg/kg P188 exhibited an increased sensitivity to
eccentric contractions
After 2 weeks of daily P188 treatment the force produced by the
TAs of mice in both 30 mg/kg and 460 mg/kg dose groups during
the eccentric contraction protocol was lower than that of saline-
treated control mice (P= 0.0001). Specifically, P188 treated mice
in both treatment groups were significantly weaker than saline
treated mice at contractions 3–7 inclusive. There was no difference
in force between mice receiving 30 mg/kg and 460 mg/kg P188
at any contraction number (Figure 2D). After 10 eccentric
contractions the TA mean tetanic forces were 42.265% (saline),
29.164.6% (P188, 30 mg/kg) and 31.361% (P188, 460 mg/kg)
of the tetanic force at the first contraction.
P188 treatment improved the histological appearance of
unstimulated, but not stimulated TA muscles
H & E sections were scored on a 5-point scale based on the
levels of inflammation, oedema and necrosis/regeneration present
(Figure S1). Representative images of each treatment group are
displayed in Figure 3. Unstimulated TA muscles from the
460 mg/kg and 30 mg/kg P188 groups had a significantly smaller
number of fibres with internalised IgG than the saline treated
group (Figure 4C), indicating that fewer fibres had sufficient
sarcolemmal damage for IgG to cross the membrane. In addition
the unstimulated muscles from the 30 mg/kg P188 group had a
significantly lower H & E score than the saline treated group
(Figure 4A). The H & E score of the 460 mg/kg group was not
different from the saline group. The number of Alizarin red
positive fibres did not differ across the groups in the unstimulated
muscles (Figure 4D).
However P188 did not improve the histological appearance of
the stimulated TA muscles. In all treatment groups, stimulated
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muscles showed a significantly higher number of IgG or Alizarin
red positive fibres, and increased H & E score compared to the
unstimulated contralateral muscles. The number of hypercon-
tracted, hypereosinophilic, swollen fibres was also significantly
higher in stimulated muscles (Figure 4B).
Tail vein bleeding time
This assay was conducted because some mice appeared to bleed
more than expected during surgery. Mice treated with 460 mg/kg
P188 for 2 weeks bled longer than mice treated with 30 mg/kg
P188 or with saline. The mean bleeding time exhibited by high
Figure 2. The effect of P188 on TA muscle function. The force frequency relationship was examined in P188-treated 9–11 month old female
mdx mice and saline-treated controls (n = 6 in each group). TA muscles from anaesthetised mdx mice underwent a series of isometric contractions in
situ induced by stimulation of the common peroneal nerve at 10, 30, 40, 50, 80, 100, 120, 150 and 180 Hz. For mice given a single dose of P188 the
force-frequency curves for the TA muscles of P188 treated mice were significantly different from that of saline-treated control mice (P = 0.034, A). Mice
treated with 30 mg/kg P188 exhibited higher specific forces than saline-treated mice when the common peroneal nerve was stimulated at 120 Hz (*
P,0.05). However after 2 weeks of treatment the force frequency curves were not different (B). In contrast 2 weeks of treatment with P188 at either
dose increased the magnitude of the drop in force production by TA muscles during a protocol of 10 eccentric contractions with a 10% length
increase (P = 0.0001; D). Post-hoc analysis revealed P188 treated mice were significantly weaker than saline treated controls at contractions 3–7
inclusive. This effect was not seen after a single dose of P188 (C). Tetanic force is expressed as a percentage of baseline isometric force produced prior
to the first stretch. * P,0.05 ** P,0.01 saline treated vs P188 30 mg/kg; # P,0.05 ## P,0.01 saline-treated vs P188, 460 mg/kg. Error bars
represent SEM.
doi:10.1371/journal.pone.0091221.g002
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dose treated mice was 76.07611.4 s compared to 47.462.4 s and
54.9 67.2 s of control and low dose treated mice respectively
(P,0.05).
Discussion
The amphiphilic, non-ionic tri-block copolymer P188 has been
suggested as a potential therapeutic for DMD due to its ability to
insert into the areas of low membrane tension that may occur in
damaged, dystrophic membranes. While systemic P188 treatment
has been shown to improve cardiac function in mdx mice and
GRMD dogs the study reported here is the first to document the
effects of P188 on dystrophic skeletal muscle function in situ, with
an intact blood supply. This test removes the confounding effects
of respiratory and cardiac function, variable body mass and the
motivational state of the mice associated with treadmill running.
In contrast to studies of the P188-treated mdx lumbrical muscle
[16] or EDL [10] in vitro, in situ muscle function testing has
Figure 3. Representative images from unstimulated and stimulated TA muscles from P188-treated and control 9–11 month old
female mdx mice. After muscle isometric force measurements and the eccentric contraction protocol were completed mice were immediately
euthanised and dissected. The stimulated and unstimulated TA muscles were mounted in the same block, cryosectioned and stained with H&E,
Alizarin red and biotinylated anti-mouse IgG antibody followed by nickel-enhanced DAB). Representative low power images of serial sections from a
single mouse from each treatment group are shown above. For each stain the upper row is images of the unstimulated TA (U) and the lower row is
images of the stimulated TA muscle (S) from the same mouse. While there appears to be a mild reduction in H and E score (Figure S1) in the
unstimulated muscle from the 30 mg/kg P188 group this difference is not seen in the stimulated muscles. Similarly there are less IgG positive fibres
(dark grey) in the unstimulated muscles of the P188-treated group but not in the stimulated muscles. For all treatment groups stimulated muscles are
expanded by marked oedema and contain greater numbers of hypercontracted (densely eosinophilic and rounded), alizarin red positive (bright red)
and IgG positive (dark grey) fibres. Scale bars represent 1000 mm.
doi:10.1371/journal.pone.0091221.g003
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Figure 4. The effect of two weeks of P188 treatment on TA muscle histology. After muscle isometric force measurements and the eccentric
contraction protocol measurements were completed mice were immediately euthanised and dissected. Both TA muscles were mounted in the same
block, cryosectioned and stained with H&E, Alizarin red or biotinylated anti-mouse IgG antibody followed by nickel-enhanced DAB. Muscle pathology
was scored in H & E sections (A) and hypereosinophilic (hypercontracted) fibres were counted (B). The number of IgG positive fibres (C) and AR
positive fibres (D) were also counted. All counts and scores were made while blind to sample identity. There was a significant increase in H & E score,
hypereosinophilic, IgG and AR positive fibres between un-stimulated (grey bars) and stimulated (black bars) TA muscles in all treatment groups. There
was a significant reduction in IgG positive fibres and H& E score in the P188-treated, unstimulated muscles. N = 5, 9–11 month old femalemdxmice in
each treatment group. Error bars represent SEM. * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0091221.g004
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demonstrated a negative effect of P188. In the current study,
treatment with P188 administered IP for 2 weeks did not change
the specific force generated by the TA muscle of homozygous
female mdx mice. Treatment did however reduce the muscles’
resistance to contraction-induced injury, resulting in an earlier and
greater drop in force during a protocol of 10 eccentric
contractions; despite reduced IgG uptake and qualitative H & E
scores in the unstimulated muscles of P188-treated mice.
Changes in membrane permeability markers following P188
treatment have been reported in previous studies. In a study in
which mdx mice received a single IP dose of 600 mg/kg P188
Evans blue dye (EBD) uptake was reduced in unexercised treated
mice compared to unexercised controls. However this significant
difference was not present after the mice were exercised on a
treadmill [24]. In addition, an increase in EBD uptake was noted
in the cardiac muscle of P188 treated (460 mg/kg) mdx mice
compared to untreated controls following an isoprotenolol
challenge that induces tachycardia and hypertension [10]. This
would suggest that although P188 may produce modest improve-
ments in membrane permeability in resting muscle, it may actually
increase membrane permeability under conditions where the
membrane is exposed to increased mechanical stress.
In the aforementioned treadmill study mice treated with
600 mg/kg P188 ran shorter distances than placebo treated
control animals and were unable to complete the treadmill test.
Although this difference was not significant (P = 0.09) it lead to a
modification of experimental protocol due to the ‘‘adverse effect’’
of P188 (Quinlan et al. 2006). In light of the results reported here
their findings would support the notion that P188 has a deleterious
effect to exercising skeletal muscle. Finally, myalgia in leg and back
muscles was frequently reported in humans on the higher doses of
IV P188 during pharmacokinetic studies [11,30]. While it is
possible that a toxic plasma level may have been reached at the
higher doses of 600 mg/kg [24] and 460 mg/kg, negative effects
on the TA muscle’s response to eccentric contraction were seen in
the current study at a dose of 30 mg/kg, at least 15 times lower
than the high doses used in previous studies [10,14,24].
Mice receiving a single dose of P188 demonstrated a modest,
but significant increase in specific force that was not seen in the
mice that were treated for two weeks. P188 has been taken to
phase III clinical trials as a rheologic agent [17] so it is possible the
drug improved perfusion through the skeletal muscle capillary
beds. Due to the mislocalisation of nNOS, normal exercised
induced hyperemia is inhibited in dystrophic muscle [2].
Therefore it is possible that the increase in specific force following
P188 injection is due to improved perfusion and hence improved
oxygen delivery to the exercising muscle. This would be expected
to be greatest during peak plasma concentrations, which would be
expected to occur by 2 hours after IP injection [24].
The rheologic action of P188 is also possibly responsible for the
increased bleeding time observed in treated mice, although the
drug has also been reported to have anticoagulant properties [31].
During surgery it was felt that P188 treated female mice bled more
than control mice. To investigate this observation further, a tail
vein bleeding time (TVBT) assay was performed in a second
cohort of mice. There was no significant difference in bleeding
time between saline and 30 mg/kg groups, however the mean
bleeding time of the 460 mg/kg treated group was significantly
prolonged. The effect of P188 on haemostasis is particularly
relevant to DMD patients because they frequently have to undergo
long, complicated spinal surgeries and often suffer fractures [32].
The previously reported beneficial effect of P188 on cardiac
output appears to be mediated by an increased compliance of the
cardiac muscle allowing increased ventricular filling (preload) and
subsequent increase in stroke volume and cardiac output [8,9].
This increase in compliance may not be beneficial in skeletal
muscle undergoing eccentric contractions, such as those occurring
during walking downstairs. The altered membrane compliance
associated with poloxamer administration has been shown to alter
functional activity of membrane proteins and change electrical
properties of membranes in vitro (Demina et al. 2005). Also while
P188 only inserts into areas of low surface tension it is expelled
from these areas as membrane tension increases to physiologic
levels [12]. Therefore although mechanically plugging a hole at
rest, the addition of P188 to a skeletal muscle membrane may
actually destabilise it further during increased mechanical stress.
Finally it has been demonstrated that P188 can act as a
permeabiliser rather than a sealant depending on a delicate
balance between adsorption of P188 to the membrane surface and
insertion of P188 into the bilayer [33]. Adsorption happens on
initial exposure and is responsible for the sealant action however
after longer exposure the molecule inserts into the bilayer and
increases permeability [33]. Therefore longer-term treatment
might conceivably increase sarcolemmal permeability further.
In conclusion, in contrast to its beneficial effects on dystrophic
cardiac function, systemically administered P188 increases con-
traction-induced injury in skeletal muscle, even at a low dose and
also increases bleeding time. Taken together, these results question
the use of P188 as a therapeutic in DMD, particularly in patients
that are still ambulant.
Supporting Information
Figure S1 Representative images of mdx TA muscles
with H & E scores of 1–5. H & E stained cryosections of TA
muscles from 6-month old WT and mdx mice. Muscles from
C57Bl/10 mice (WT) show no pathology and have peripherally
located nuclei. Mdx muscles given a score of 1 exhibit centrally
located nuclei (CN) and fibre size variation but minimal necrosis.
A score of 2 is given if muscle has the features of score 1 but with
signs of active necrosis (N) and regeneration (R). Score 3 is given if
this regeneration and necrosis is extensive, hypercontracted fibres
are present but oedema is mild. Muscles receive score 4 if oedema
(O) is moderate with numerous hypercontracted fibres (H) and
muscle with score 5 exhibit all the features of scores 1–4 and
extensive oedema and grossly disrupted fibres (D). Muscles
exhibiting features intermediate between two scores were given
an additional 0.5. Scale bars represent 100 mm.
(TIFF)
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